|
1
|
Foley C and Mitsiades N: Moving beyond the
androgen receptor (AR): Targeting AR-interacting proteins to treat
prostate cancer. Horm Cancer. 7:84–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Y, Sawyers CL and Scher HI: Targeting
the androgen receptor pathway in prostate cancer. Curr Opin
Pharmacol. 8:440–448. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park HW and Guan KL: Regulation of the
Hippo pathway and implications for anticancer drug development.
Trends Pharmacol Sci. 34:581–589. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson R and Halder G: The two faces of
Hippo: Targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bertini E, Oka T, Sudol M, Strano S and
Blandino G: YAP: At the crossroad between transformation and tumor
suppression. Cell Cycle. 8:49–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci USA. 103:pp. 12405–12410. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Identification and validation of oncogenes in liver cancer
using an integrative oncogenomic approach. Cell. 125:1253–1267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steinhardt AA, Gayyed MF, Klein AP, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of
Yes-associated protein in common solid tumors. Hum Pathol.
39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernandez-L A, Northcott PA, Dalton J,
Fraga C, Ellison D, Angers S, Taylor MD and Kenney AM: YAP1 is
amplified and up-regulated in hedgehog-associated medulloblastomas
and mediates Sonic hedgehogdriven neural precursor proliferation.
Genes Dev. 23:2729–2741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT,
Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an
independent prognostic marker in hepatocellular carcinoma. Cancer.
115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB; AOCS Study group, ; Bowtell DD and Harvey KF:
The Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Xu ZP, Yang YC, Zhu JS, Zhou Z
and Chen WX: Expression of Yes-associated protein in gastric
adenocarcinoma and inhibitory effects of its konckdown on gastric
cancer cell proliferation and metastasis. Int J Immunopathol
Pharmacol. 25:583–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang W, Nandakumar N, Shi Y, Manzano M,
Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, et
al: Downstream of mutant KRAS, the transcription regulator YAP is
essential for neoplastic progression to pancreatic ductal
adenocarcinoma. Sci Sig. 7:ra422014. View Article : Google Scholar
|
|
18
|
Zhang L, Yang S, Chen X, Stauffer S, Yu F,
Lele SM, Fu K, Datta K, Palermo N, Chen Y and Dong J: The Hippo
pathway effector YAP regulates motility, invasion, and
castration-resistant growth of prostate cancer cells. Mol Cell
Biol. 35:1350–1362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sheng X, Li WB, Wang DL, Chen KH, Cao JJ,
Luo Z, He J, Li MC, Liu WJ and Yu C: YAP is closely correlated with
castration-resistant prostate cancer, and downregulation of YAP
reduces proliferation and induces apoptosis of PC-3 cells. Mol Med
Rep. 12:4867–4876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Planque N and Perbal B: A structural
approach to the role of CCN (CYR61/CTGF/NOV) proteins in
tumourigenesis. Cancer Cell Int. 3:152003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:pp. E2441–E2450. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong J, Feldmann G, Huang J, Wu S, Zhang
N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D:
Elucidation of a universal size-control mechanism in Drosophila and
mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao B, Li L, Wang L, Wang CY, Yu J and
Guan KL: Cell detachment activates the Hippo pathway via
cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu FX, Zhao B, Panupinthu N, Jewell JL,
Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al:
Regulation of the Hippo-YAP pathway by G-Protein-Coupled receptor
signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li W, Wang L, Katoh H, Liu R, Zheng P and
Liu Y: Identification of a tumor suppressor relay between the FOXP3
and the Hippo pathways in breast and prostate cancers. Cancer Res.
71:2162–2171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M
and Fan HY: Correction: YAP promotes ovarian cancer cell
tumorigenesis and is indicative of a poor prognosis for ovarian
cancer patients. PLoS One. 11:e01527122016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ehmer U and Sage J: Control of
proliferation and cancer growth by the Hippo signaling pathway. Mol
Cancer Res. 14:127–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou Z, Zhu JS, Gao CP, Li LP, Zhou C,
Wang H and Liu XG: siRNA targeting YAP gene inhibits gastric
carcinoma growth and tumor metastasis in SCID mice. Oncol Lett.
11:2806–2814. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng TY, Wu MS, Hua KT, Kuo ML and Lin
MT: Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. World
J Gastroenterol. 20:1694–1700. 2014. View Article : Google Scholar : PubMed/NCBI
|
